David Rizzieri, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, David Rizzieri, MD sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

David Rizzieri, MD: 8 sponsored US clinical trials, none currently recruiting.

David Rizzieri, MD sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplasia, with 3 trials.

Upper-quartile sponsor footprint

David Rizzieri, MD sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01373229
COMPLETED Phase 2

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
TERMINATED Phase 2

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

NCT00511043
COMPLETED Phase 2

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

NCT00578942
COMPLETED Phase 1

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

NCT00586690
COMPLETED Phase 1

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

NCT00586703
COMPLETED Phase 2

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

NCT00580034
COMPLETED Phase 2

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

NCT00004143

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5

Therapeutic Areas

Myelodysplasia 3
Myeloma 3
Leukemia 3
Solid Tumors 2
Lymphoma 2
Hodgkin's Disease 1
Non-Hodgkin's Lymphoma 1

How the David Rizzieri, MD early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Myelodysplasia (3 trials), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

David Rizzieri, MD: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share David Rizzieri, MDAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this David Rizzieri, MD page

8 registered trials is a research-attention snapshot, not an endorsement of David Rizzieri, MD or any single study.

  • None of David Rizzieri, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Myelodysplasia is the condition David Rizzieri, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplasia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

David Rizzieri, MD pipeline card: 8 registered trials from official public datasets.Report a data error.